FDA Alignment to Advance ProstACT Global Phase 3 Trial

FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States.FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care combination